## **Supporting Information**

## Tumor-specific activated photodynamic therapy with an oxidation regulated strategy for enhancing anti-tumor efficacy

Huan Liang <sup>a, b</sup>, Zhanwei Zhou <sup>c</sup>, Renjie Luo <sup>a</sup>, Mangmang Sang <sup>a</sup>, Bowen Liu <sup>d</sup>, Minjie Sun <sup>c</sup>, Wei Qu <sup>d</sup>, Feng Feng <sup>d, e\*</sup>, Wenyuan Liu <sup>a, b\*</sup>

a Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China

b Key Laboratory of Drug Quality Control and Pharmacovigilance (China

Pharmaceutical University), Ministry of Education, Nanjing 210009, China

c State Key Laboratory of Natural Medicines and Department of Pharmaceutics,

China Pharmaceutical University, Nanjing, 210009, China

d Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24

Tong Jia Xiang, Nanjing 210009, China

e Jiangsu Food and Pharmaceutical Science College, Huaian 223003, China

\* Corresponding authors:

Prof. Wenyuan Liu, Tel/Fax: 86 25 83271038, Email: <u>liuwenyuan@cpu.edu.cn</u> Prof. Feng Feng, Tel/Fax: 86 25 86185216, E-mail: <u>fengfeng@cpu.edu.cn</u>



Figure S1. The purity of GA determined by High-performance liquid chromatography (HPLC).



Figure S2. HPLC analysis of (A) HA-GA@Ce6. (b) HA-GA@Ce6 after 2 min laser irradiated. (c) HA. (d) GA.







Figure S3. (A) Synthesis scheme of HA-GA. (B) <sup>1</sup>H NMR spectrum of bis(3bromopropyl) oxalate-linker. (C) <sup>1</sup>H NMR spectrum of GA-Linker covalent bonding compound. (D) <sup>1</sup>H NMR spectrum of HA-GA. (E) FTIR spectrum of GA-Linker (a), HA-GA (b) and HA (c).



Figure S4. Standard Curve of (A) GA and (B) Ce6.



Figure S5. Variation in the size of HA-GA@Ce6 and HA-GA at storage for 7 days.



Figure S6. The depletion of GSH and the elevation of ROS level induced by NEM.





Figure S7. The fluorescence emission spectrum of HA-GA@Ce6/DiR.

Figure S8. The representative *ex*-tumor images taken on Day 21 after the first treatment.